Although the topline results (for relapse rate and lesion activity) are definitely disappointing, I think it's too early to say that Dirucotide is no use for RRMS. According to BioMS's press release, Dirucotide did provide a statistically significant benefit in terms of EDSS and MFCS. So it might turn out to be usefull for RRMS as part of a two-drug regimen. It would hopefully reduce neurodegeneration, while another drug would be used to reduce inflammation.
It'll be interesting to see the results of the phase III for SPMS.